Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology

Understanding IPAN and PAF

At a Glance

IPAN is a broad diagnosis of measurable autonomic nerve dysfunction without an identified cause, while Pure Autonomic Failure is a more specific syndrome of isolated autonomic failure, often causing a blood pressure drop when standing. Testing and follow-up guide management.

Receiving a diagnosis of Idiopathic Peripheral Autonomic Neuropathy (IPAN) or Pure Autonomic Failure (PAF) often comes after a long and exhausting search for answers [1]. Because these conditions are rare and their symptoms—like fainting, dizziness, or digestive trouble—can look like many other things, it is often a long time, sometimes 5 to 7 years, before patients find a name for what they are experiencing, though the diagnosis can be revised as new symptoms or test results appear [2][3].

While the term “idiopathic” means doctors have not yet found an underlying cause like diabetes or an infection, it does not mean your symptoms are “all in your head” [4]. On the contrary, these diagnoses are based on real, measurable dysfunction in the autonomic nervous system, the system that controls your blood pressure, heart rate, and digestion [5][6]. Some patients have objective dysfunction without a definitive structural marker, but the physiological impairment is real and verifiable by testing.

Understanding the Difference: IPAN vs. PAF

While both conditions involve the autonomic nerves, they describe slightly different situations:

  • Idiopathic Peripheral Autonomic Neuropathy (IPAN): This is a broad descriptive category of an unknown underlying cause. It means you have documented damage to the autonomic nerves, but standard tests have evaluated for and not found common causes like diabetes, vitamin deficiencies, or autoimmune diseases [4][7]. It can affect just one part of the system (like your sweat glands) or be more widespread [5].
  • Pure Autonomic Failure (PAF): This is a clinical syndrome of isolated autonomic failure, typically with postganglionic sympathetic denervation [8]. It is called “pure” because, at least initially, it only affects the autonomic system and does not involve the brain’s motor or cognitive functions [9]. It is characterized by a slow, chronic decline in autonomic control, most notably a significant drop in blood pressure when standing, known as orthostatic hypotension [10].

Comparison of Key Features

Feature Idiopathic Autonomic Neuropathy (IPAN) Pure Autonomic Failure (PAF)
Scope Broad descriptive category of unknown underlying cause [4] Clinical syndrome of isolated autonomic failure, typically with postganglionic sympathetic denervation [8]
Typical Onset Can be sudden or gradual [7] Very gradual and insidious [8]
Nerve Damage May involve various types of nerve fibers [7] Specifically involves the peripheral sympathetic nerves [11]
Protein Markers Usually no specific protein markers [5] Often involves abnormal alpha-synuclein, though testing is not definitive alone [12]

The Biology of Autonomic Symptoms

In both IPAN and PAF, the primary problem is a failure of communication between your brain and your body. Two biological factors are key to understanding why this happens:

1. The Disappearance of Norepinephrine

Norepinephrine is a chemical messenger (neurotransmitter) that your sympathetic nerves release to tell your blood vessels to tighten and your heart to beat faster when you stand up [13]. In PAF, the nerve endings that should release this chemical actually wither away (denervation) [11]. Without enough norepinephrine, your blood vessels stay relaxed, gravity pulls your blood toward your feet, and your blood pressure drops, leading to lightheadedness or fainting [14][15].

2. Alpha-Synuclein Deposits

In patients with PAF, researchers often find abnormal clumps of a protein called alpha-synuclein within the autonomic nerves [8]. These deposits are considered a hallmark of “synucleinopathies,” a family of diseases that includes Parkinson’s [16]. In PAF, these deposits are found primarily in the peripheral nerves (the ones outside your brain and spinal cord), which is why the condition is “purely” autonomic for many years [12][17]. However, alpha-synuclein is not routinely established in a living patient, and a negative biomarker does not exclude PAF.

The Diagnostic Journey

Because these conditions are “diagnoses of exclusion,” your medical team must perform a systematic evaluation to investigate other possibilities [5]. This process can feel repetitive, but it is necessary to ensure the diagnosis is accurate. Common steps include:

  • Autonomic Reflex Screen: A series of tests, including the “tilt-table test,” to measure how your heart rate and blood pressure respond to changes in position [6][15].
  • Blood Tests: Checking for diabetes, vitamin B12 deficiency, and rare antibodies that can attack the autonomic system [18][19].
  • Skin Biopsy: A small sample of skin may be taken to count the density of your small nerve fibers or to look for those alpha-synuclein deposits [8][12].
  • Catecholamine Levels: Measuring the amount of norepinephrine in your blood while you are lying down versus standing up [14][20].

Living with Uncertainty

It is normal to feel frustrated by words like “idiopathic” or “failure.” However, receiving a clear diagnosis—even one that describes what isn’t known—is a vital step toward management. Once the autonomic dysfunction is identified, you and your doctor can move away from searching for a cause and focus on strategies to manage blood pressure, improve digestion, and regain your quality of life [21]. Because these conditions can change over time, regular follow-ups with an autonomic specialist are essential to monitor your symptoms and adjust your care plan [14][22].

Common questions in this guide

What is the difference between IPAN and pure autonomic failure?
IPAN is a broad label for documented dysfunction or damage in the autonomic nerves when a common cause has not been identified. Pure autonomic failure is a more specific syndrome in which autonomic failure occurs in relative isolation, often causing a substantial drop in blood pressure when standing. PAF usually does not involve motor or thinking problems early in the condition.
Does the word idiopathic mean that my autonomic symptoms are not real?
No. Idiopathic means that testing has not identified an underlying cause; it does not mean the symptoms are psychological or imagined. Autonomic dysfunction can be measured with tests of blood pressure, heart rate, sweating, nerve function, and related responses.
What tests are used to evaluate IPAN or PAF?
Evaluation may include an autonomic reflex screen with tilt-table testing, blood tests for conditions such as diabetes or vitamin B12 deficiency, and measurements of norepinephrine while lying down and standing. A skin biopsy may be used to assess small nerve fibers or look for alpha-synuclein deposits. No single test establishes every case, so clinicians interpret the results together.
Why do IPAN or PAF cause dizziness or fainting when I stand?
When you stand, the autonomic nerves should help blood vessels tighten and support blood pressure. If too little norepinephrine is released, blood can collect in the legs and blood pressure may fall, causing lightheadedness, dizziness, or fainting. This blood pressure drop is called orthostatic hypotension.
What does alpha-synuclein have to do with pure autonomic failure?
Abnormal alpha-synuclein deposits are often found in the autonomic nerves of people with PAF and are associated with a group of conditions called synucleinopathies. Testing for these deposits is not definitive by itself and is not routinely established in every living patient. A negative biomarker result does not rule out PAF.
How are IPAN and PAF monitored and managed over time?
Regular follow-up with an autonomic specialist can track symptoms, identify new changes, and determine whether the working diagnosis needs to be revised. Care may focus on managing blood pressure and digestive symptoms through individualized non-drug strategies and, when appropriate, medication. Your clinician can adjust the plan as your condition changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific tests (like an Autonomic Reflex Screen or sweat testing) were used to confirm my diagnosis?
  2. 2.Do my results show 'postganglionic' or 'preganglionic' involvement, and what does that mean for my long-term outlook?
  3. 3.Were my norepinephrine levels tested, and if so, how did they respond when I stood up?
  4. 4.Given my symptoms, should I have a skin biopsy to look for alpha-synuclein deposits?
  5. 5.What is the plan for monitoring me over time to see if my symptoms change or new ones appear?
  6. 6.Are there specific non-drug strategies or medications you recommend for managing my blood pressure or digestive symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Abnormal dopamine transporter imaging in pure autonomic failure: a potential biomarker of central nervous system involvement.

    Alnasser Alsukhni R, Vichayanrat E, Koay S, et al.

    European journal of neurology 2024; (31(3)):e16169 doi:10.1111/ene.16169.

    PMID: 38085264
  2. 2

    Natural history of pure autonomic failure: A United States prospective cohort.

    Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al.

    Annals of neurology 2017; (81(2)):287-297 doi:10.1002/ana.24877.

    PMID: 28093795
  3. 3

    Diagnosing Premotor Multiple System Atrophy: Natural History and Autonomic Testing in an Autopsy-Confirmed Cohort.

    Vichayanrat E, Valerio F, Koay S, et al.

    Neurology 2022; (99(11)):e1168-e1177 doi:10.1212/WNL.0000000000200861.

    PMID: 35790426
  4. 4

    Autonomic Neuropathies.

    Cook GA, Kissel JT, Dimachkie MM

    Neurologic clinics 2025; (43(4)):851-872 doi:10.1016/j.ncl.2025.05.013.

    PMID: 41162000
  5. 5

    Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies.

    Lamotte G, Sandroni P

    Current neurology and neuroscience reports 2022; (22(12)):823-837 doi:10.1007/s11910-022-01240-4.

    PMID: 36376534
  6. 6

    Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology.

    Cheshire WP, Freeman R, Gibbons CH, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(2)):666-682 doi:10.1016/j.clinph.2020.11.024.

    PMID: 33419664
  7. 7

    Autonomic Peripheral Neuropathy.

    Freeman R

    Continuum (Minneapolis, Minn.) 2020; (26(1)):58-71 doi:10.1212/CON.0000000000000825.

    PMID: 31996622
  8. 8

    Pure autonomic failure and the differential diagnosis of autonomic peripheral neuropathies.

    González-Duarte A, Varma-Doyle A, Freeman R

    Current opinion in neurology 2021; (34(5)):675-682 doi:10.1097/WCO.0000000000000985.

    PMID: 34392300
  9. 9

    Autonomic Dysfunction in α-Synucleinopathies.

    Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, et al.

    Frontiers in neurology 2019; (10()):363 doi:10.3389/fneur.2019.00363.

    PMID: 31031694
  10. 10

    Pure autonomic failure.

    Brown TP

    Practical neurology 2017; (17(5)):341-348 doi:10.1136/practneurol-2016-001559.

    PMID: 28717053
  11. 11

    Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies.

    Lamotte G, Holmes C, Sullivan P, et al.

    Annals of clinical and translational neurology 2020; (7(12)):2450-2460 doi:10.1002/acn3.51243.

    PMID: 33216462
  12. 12

    Cutaneous phosphorylated-synuclein: an early diagnostic biomarker for pure autonomic failure.

    Koay S, Provitera V, Caporaso G, et al.

    Journal of neurology, neurosurgery, and psychiatry 2025; (96(5)):500-507 doi:10.1136/jnnp-2024-334615.

    PMID: 39608812
  13. 13

    Multiple system atrophy: using clinical pharmacology to reveal pathophysiology.

    Jordan J, Shibao C, Biaggioni I

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2015; (25(1)):53-9 doi:10.1007/s10286-015-0271-4.

    PMID: 25757803
  14. 14

    Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure.

    Koay S, Vichayanrat E, Bremner F, et al.

    Annals of clinical and translational neurology 2025; (12(11)):2170-2180 doi:10.1002/acn3.70140.

    PMID: 40696849
  15. 15

    Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies.

    Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al.

    Annals of neurology 2018; (83(3)):522-531 doi:10.1002/ana.25170.

    PMID: 29405350
  16. 16

    Autonomic failure: Clinicopathologic, physiologic, and genetic aspects.

    Younger DS

    Handbook of clinical neurology 2023; (195()):55-102 doi:10.1016/B978-0-323-98818-6.00020-0.

    PMID: 37562886
  17. 17

    Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.

    Donadio V, Incensi A, El-Agnaf O, et al.

    Scientific reports 2018; (8(1)):14246 doi:10.1038/s41598-018-32588-8.

    PMID: 30250046
  18. 18

    Autoimmune autonomic disorders.

    Mckeon A, Benarroch EE

    Handbook of clinical neurology 2016; (133()):405-16.

    PMID: 27112689
  19. 19

    Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

    Golden EP, Vernino S

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(3)):277-288 doi:10.1007/s10286-019-00611-1.

    PMID: 31093868
  20. 20

    Unveiling autonomic failure in synucleinopathies: Significance in diagnosis and treatment.

    Clement G, Cavillon G, Vuillier F, et al.

    Revue neurologique 2024; (180(1-2)):79-93 doi:10.1016/j.neurol.2023.12.004.

    PMID: 38216420
  21. 21

    The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.

    Gibbons CH, Schmidt P, Biaggioni I, et al.

    Journal of neurology 2017; (264(8)):1567-1582 doi:10.1007/s00415-016-8375-x.

    PMID: 28050656
  22. 22

    Pure autonomic failure: a natural history study of the Queen Square cohort.

    Chiaro G, Vichayanrat E, Koay S, et al.

    Brain : a journal of neurology 2026; (149(2)):606-619 doi:10.1093/brain/awaf191.

    PMID: 40397689

This page about IPAN and PAF is for informational purposes only and does not constitute medical advice. An autonomic specialist should interpret your test results and guide your individualized care.

Get notified when new evidence is published on idiopathic peripheral autonomic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.